SCL Science Inc.
Financials
Valuation Metrics
SCL Science Inc.'s Market Cap is ₩582B. At end of 2025 it was ₩782B. Ranked #1629 of 2,436 in KR market (top 67%), #966 of 1,649 on KOSDAQ (top 59%), #65 of 96 in Health Care Equipment & Services (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 58.20B KRW | KR#1,629/2,436 Sec#65/96 |
| Revenue | 27.40B KRW | KR#2,060/2,436 Sec#66/96 |
| Net Income | -3.50B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 77.44B KRW | KR#1,927/2,436 Sec#60/96 |
| Net Assets | 22.51B KRW | KR#2,246/2,436 Sec#85/96 |
| Employees | 63 | KR#1,919/2,436 Sec#79/96 |
| Value | ||
| P/B | 2.59x | KR#2,050/2,436 Sec#73/96 |
| P/S | 2.12x | KR#1,859/2,436 Sec#52/96 |
| FCF Yield | -5.24% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -15.53% | KR#2,003/2,436 Sec#67/96 |
| ROA | -4.51% | KR#1,870/2,436 Sec#60/96 |
| Op. Margin | -9.84% | KR#1,977/2,436 Sec#63/96 |
| Revenue Growth | 237.88% | KR#57/2,436 Sec#4/96 |
| Financial Health | ||
| Debt Ratio | 343.96% | KR#2,204/2,436 Sec#89/96 |
| Total Debt | 25.45B KRW | KR#1,270/2,436 Sec#33/96 |
| FCF | -3.05B KRW | KR#1,398/2,436 Sec#46/96 |
| Cash | 2.66B KRW | KR#2,186/2,436 Sec#86/96 |
| Current Ratio | 0.90x | KR#1,927/2,436 Sec#85/96 |
| Performance | ||
| 1Y Return | -37.33% | KR#1,773/2,436 Sec#59/96 |
| 1M Return | 0.71% | KR#812/2,436 Sec#39/96 |
| From 52W High | -47.35% | KR#1,075/2,436 Sec#40/96 |
| 1Y MDD | -61.58% | KR#1,498/2,436 Sec#49/96 |
| Trading | ||
| Volume | 91,487 shares | KR#988/2,436 Sec#40/96 |
| Foreign Own. | 0.63% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -93 KRW | KR—/2,436 Sec—/96 |
| BPS | 694 KRW | KR#2,353/2,436 Sec#91/96 |
Company Info
SCL Science, established in 2010 and listed on KOSDAQ in 2019, is a bio venture company. It primarily develops and produces medical hemostatic agents using biomimetic technology inspired by mussel adhesion, alongside operating bio-logistics and data platform-based digital healthcare businesses. The company is developing a range of hemostatic products applicable to patients with blood coagulation disorders and expanding its product portfolio with polymer modification technology, growing into a healthcare company. SCL Science is headquartered in Yeongdeungpo-gu, Seoul.